Future Market Insights’ updated report predicts the global postmenopausal osteoporosis treatment market size to reach US$ 13.1 billion in 2024. Global postmenopausal osteoporosis treatment demand is anticipated to surge at a 5.8% CAGR, guiding total market valuation to reach a staggering US$ 23.0 billion by 2034.
Bisphosphonates remain the first line of treatment for postmenopausal osteoporosis owing to their higher efficacy and low cost. Patients are increasingly consuming these medications to manage osteoporosis and its symptoms. The target segment is set to rise at 5.6% CAGR.
Future Outlook for Postmenopausal Osteoporosis Treatment Market:
| Attributes | Key Insights |
|---|---|
| Base Market Value (2023) | US$ 12.3 billion |
| Market Size in 2024 | US$ 13.1 billion |
| Market Revenue in 2034 | US$ 23.0 billion |
| Value-based CAGR (2024 to 2034) | 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Postmenopausal osteoporosis is becoming a common health condition in women after menopause when estrogen levels decline. It causes bones to become weak and brittle, necessitating effective treatment approaches like osteoporosis drugs.
Women with postmenopausal osteoporosis are increasingly consuming medications like bisphosphonates to manage the condition. This is providing impetus for the growth of the postmenopausal osteoporosis therapeutics market.
According to the World Health Organization (WHO), the world population aged 60 and above is projected to reach around 2.1 million by 2050. This will fuel demand for postmenopausal osteoporosis medications as older people are more prone to osteoporosis.
Patients are increasingly consuming oral medications for postmenopausal osteoporosis due to their low cost and high effectiveness. High spending on these medications is anticipated to boost sales growth in the market. To benefit from this, new oral agents like selective receptor modulators (SERMs) and cathepsin K inhibitors are being developed by companies.
Availability of various drugs for postmenopausal osteoporosis treatment is projected to boost sales growth. Both patients and healthcare professionals choose a specific drug type based on its efficacy and cost. Many new non-hormonal osteoporosis treatments for postmenopausal women are making their way into the market.
Escalating emphasis on bone health and preventive measures to reduce the risk of osteoporosis is encouraging people to consume calcium, Vitamin D, and other medications. This will positively impact postmenopausal osteoporosis medication sales through 2034.
Key players are striving to develop cost-effective treatment options for postmenopausal osteoporosis. This will make osteoporosis management affordable and accessible to general public.
On the other hand, side effects of postmenopausal osteoporosis medications are anticipated to limit market growth. Bisphosphonate drugs like risedronate and alendronate often cause nausea, heartburn, and vomiting, demotivating patients to consume them.
Although hormone replacement therapy for postmenopausal osteoporosis can effectively reduce bone loss and relieve other symptoms, it can increase the risk of stroke, blood clots, and breast cancer. These side effects are believed to limit growth of the target industry.
Global postmenopausal osteoporosis treatment demand grew at a healthy CAGR of 7.5% during the historical period, with total market valuation reaching US$ 12.3 billion in 2023. In the next ten years, a CAGR of 5.8% has been predicted for the target industry, depicting a deduction of 1.7% CAGR from the historical period.
Multiple factors are anticipated to stimulate growth of the postmenopausal osteoporosis drug market during the forecast period. These include growing awareness of osteoporosis and its treatments, introduction of novel drug candidates, and favorable government support.
To gain maximum benefits, key players are concentrating on developing new biopharmaceuticals like monoclonal antibodies. Similarly, high efficacy of hormone replacement therapies is encouraging their popularity and adoption among patients.
Many companies are also looking to develop injectable treatments for postmenopausal osteoporosis. This will positively impact market growth during the assessment period.
Principal Consultant
High Prevalence of Osteoporosis among Older Women
One of the prominent factors dictating growth of the postmenopausal osteoporosis therapeutics market is the increasing incidence of osteoporosis in women going through menopause. These women have low levels of estrogen, resulting in a decrease in bone density and high risk of fractures.
In order to treat postmenopausal osteoporosis and reduce the risk of fractures, patients opt for medications like bisphosphonates. This, in turn, is anticipated to fuel sales of postmenopausal osteoporosis drugs and boost market growth.
Increasing Diagnostic Rates
Osteoporosis is becoming a serious health issue due to its devastating effects on the human body. As a result, diagnosing and treating this medical condition becomes necessary, prompting people to opt for various diagnostic tests and treatments.
New diagnostic techniques like bone density scans (DEXA scans) are allowing for earlier detection of osteoporosis. Thus, rising diagnostic rates of osteoporosis will eventually lead to higher demand for postmenopausal osteoporosis drugs through 2034.
The section below comprehensively evaluates three interrelated markets: the global postmenopausal osteoporosis medication industry, the menopause treatment market, and the osteonecrosis treatment industry. It dissects each market's distinctive characteristics, encompassing their respective CAGRs, while delving into the pivotal factors influencing their growth trajectories.
Global Postmenopausal Osteoporosis Treatment Market Analysis:
| Attribute | Global Postmenopausal Osteoporosis Treatment Market Forecast |
|---|---|
| CAGR (2024 to 2034) | 5.8% |
| Growth Factor | Escalating prevalence of osteoporosis among elderly women is providing impetus for market growth. |
| Key Trends in Postmenopausal Osteoporosis Treatment Market | Key growth shaping trends include development of new biologic therapies for postmenopausal osteoporosis, growing interest in personalized medicine, and surging adoption of digital health solutions like wearable devices and mobile apps to improve patient engagement and adherence in osteoporosis management. |
Global Menopause Treatment Market Forecast:
| Attribute | Global Menopause Treatment Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 5.6% |
| Growth Factor | Increasing prevalence of post-menopausal syndrome is a prominent factor boosting growth of the menopause treatment market. |
| Key Trends | Growing acceptance of menopause treatments due to growing health awareness will benefit the market. |
Global Osteonecrosis Treatment Market Analysis:
| Attribute | Global Osteonecrosis Treatment Industry Outlook |
|---|---|
| CAGR (2024 to 2034) | 4.9% |
| Growth Factor | Surging geriatric population and increasing incidence of osteonecrosis are fueling market growth. |
| Key Trends | Development of novel osteonecrosis drugs and growing preference for non-invasive treatments are key trends influencing sales growth. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below shows the estimated growth rates of the top key countries. South Korea and Japan are set to record high CAGRs of 8.0% and 7.3%, respectively, through 2034.
| Countries | CAGR (2024 to 2034) |
|---|---|
| United States | 5.9% |
| United Kingdom | 6.7% |
| China | 6.6% |
| Japan | 7.3% |
| South Korea | 8.0% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain the top consumers of postmenopausal osteoporosis medications, with predicted valuations of US$ 4.0 billion and US$ 3.6 billion, respectively, in 2034.
| Countries | Market Revenue (2034) |
|---|---|
| United States | US$ 4.0 billion |
| United Kingdom | US$ 929.0 million |
| China | US$ 3.6 billion |
| Japan | US$ 2.5 billion |
| South Korea | US$ 1.5 billion |
The United States postmenopausal osteoporosis treatment market is forecast to exhibit a CAGR of 5.9% during the next decade, totaling a staggering valuation of US$ 4.0 billion by 2034. This is attributable to surging incidence of osteoporosis in the nation as well as availability of favorable reimbursement policies for postmenopausal osteoporosis treatment.
According to the Bone Health & Osteoporosis Foundation (BHOF), around 10 million Americans have osteoporosis, with incidence greater in women. This high prevalence is creating demand for postmenopausal osteoporosis medications in the nations, and the trend will persist through 2034.
Rise in early osteoporosis diagnosis is another key factor propelling demand for osteoporosis drugs. Similarly, strong presence of leading pharmaceutical and biopharmaceutical giants is improving the United States market share.
The United States is home to several top biopharmaceutical companies, including Amgen. These companies are constantly striving to develop novel and effective medications for osteoporosis treatment.
FMI’s latest analysis estimates China's postmenopausal osteoporosis industry value to total US$ 3.6 billion by 2034, registering a CAGR of 6.6% throughout the forecast period. This is due to China’s rapidly increasing geriatric population, favorable government support, and ongoing new drug launches.
China is witnessing a spike in the geriatric population, which will majorly guide postmenopausal osteoporosis drug shipments throughout the forecast period. Older women are more prone to postmenopausal osteoporosis, prompting them to opt for various treatments.
Rising healthcare expenditure and surging awareness about postmenopausal osteoporosis are also sculpting postmenopausal osteoporosis therapeutic market growth in China. High healthcare spending by the Chinese government to make osteoporosis treatments affordable and accessible to the general public will bode well for the market.
The section below provides deeper insights into top segments and their respective values & shares in the global market. This information can help companies act accordingly and strengthen their presence in lucrative regions.
Based on drug type, the bisphosphonates segment is poised to grow at 5.6% CAGR through 2034. By distribution channel, the hospital pharmacies category will record a CAGR of 5.4% from 2024 to 2034.
| Top Segment | Bisphosphonates (Drug Type) |
|---|---|
| CAGR (2024 to 2034) | 5.6% |
Bisphosphonates remain the most preferred drugs for treating postmenopausal osteoporosis. This can be attributed to high adoption of bisphosphonates for postmenopausal osteoporosis due to their higher efficacy in reducing the risk of bone loss. The latest analysis estimates bisphosphonates demand to soar at 5.6% CAGR through 2034.
Bisphosphonates such as alendronate and risedronate are the first line of treatment for women at high risk of osteoporosis fractures. These medications effectively treat postmenopausal osteoporosis by reducing the rate of bone loss.
Escalating demand for targeted therapeutics and a shift in prescribing patterns towards bisphosphonates are anticipated to boost segment growth. Bisphosphonates work by slowing down bone breakdown and improving bone density.
Bisphosphonates are effective in treating various solid tumors affecting bones, such as multiple myeloma, by reducing skeletal morbidity. These medications are increasingly being used in combination with anticancer therapies to prevent skeletal problems and alleviate bone pain.
Although bisphosphonates currently dominate the market, emerging trends suggest a transition towards more contemporary precision-targeted therapies and biopharmaceuticals. For instance, hormone replacement therapy is becoming a top contender in postmenopausal osteoporosis management.
Many patients are choosing hormone replacement therapy for postmenopausal osteoporosis due to its promising results. As a result, a rapid CAGR has been predicted for the target segment between 2024 and 2034.
| Top Segment | Hospital Pharmacies (Distribution Channel) |
|---|---|
| CAGR (2024 to 2034) | 5.4% |
Based on distribution channel, hospital pharmacies held 42.0% of the postmenopausal osteoporosis treatment market share in 2023. Over the next ten years, the target segment is forecast to record a CAGR of 5.4%.
Hospital pharmacies are centralized distribution channels for medication procurement, storage, dispensing, and management within healthcare institutions. They dispense postmenopausal osteoporosis medications to patients undergoing treatments in hospitals.
Leading manufacturers of postmenopausal osteoporosis drugs are rigorously investing in research and development to introduce novel therapies for postmenopausal osteoporosis with improved efficacy and fewer side effects. They are investigating biologics that target specific pathways involved in bone loss.
Companies are also striving to get fast-track approvals for their new drugs. Similarly, the market is witnessing strategies like partnerships, distribution agreements, collaborations, mergers, and acquisitions as players look to strengthen their presence and improve their market shares.
Key Players in the Postmenopausal Osteoporosis Treatment Market:
Recent Developments:
The global market is estimated to be valued at US$ 13.1 billion in 2024.
Global demand is poised to grow at a CAGR of 5.8% through 2034.
By 2034, the global market size is set to reach US$ 23.0 billion.
The target industry registered a CAGR of 7.5% from 2019 to 2023.
The United States is poised to record a CAGR of 5.9% through 2034.
Bisphosphonates.
The FDA recently approved romosozumab for osteoporosis in postmenopausal women.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Manufacturer 3.5.1.2. Mid-Level Participants (Traders) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Drug Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Drug Type, 2024 to 2034 5.3.1. Bisphosphonates 5.3.2. Vitamin D3 5.3.3. Estrogen Agonist/Antagonist 5.3.4. Hormone Replacement Therapy 5.3.5. Parathyroid Hormone Therapy 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Drug Type, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Hospital Pharmacies 6.3.2. Retail Pharmacies 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ billion) & Volume (Unit Pack) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. United States 8.2.1.2. Canada 8.2.2. By Drug Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Drug Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Drug Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Drug Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ billion) & Volume (Unit Pack) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ billion) & Volume (Unit Pack) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East & Africa 14.2.2. By Drug Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United States 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2024 15.1.2.1. By Drug Type 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2024 15.2.2.1. By Drug Type 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2024 15.3.2.1. By Drug Type 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2024 15.4.2.1. By Drug Type 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2024 15.5.2.1. By Drug Type 15.5.2.2. By Distribution Channel 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2024 15.6.2.1. By Drug Type 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2024 15.7.2.1. By Drug Type 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2024 15.8.2.1. By Drug Type 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2024 15.9.2.1. By Drug Type 15.9.2.2. By Distribution Channel 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2024 15.10.2.1. By Drug Type 15.10.2.2. By Distribution Channel 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2024 15.11.2.1. By Drug Type 15.11.2.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2024 15.12.2.1. By Drug Type 15.12.2.2. By Distribution Channel 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2024 15.13.2.1. By Drug Type 15.13.2.2. By Distribution Channel 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2024 15.14.2.1. By Drug Type 15.14.2.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2024 15.15.2.1. By Drug Type 15.15.2.2. By Distribution Channel 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2024 15.16.2.1. By Drug Type 15.16.2.2. By Distribution Channel 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2024 15.17.2.1. By Drug Type 15.17.2.2. By Distribution Channel 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2024 15.18.2.1. By Drug Type 15.18.2.2. By Distribution Channel 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2024 15.19.2.1. By Drug Type 15.19.2.2. By Distribution Channel 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2024 15.20.2.1. By Drug Type 15.20.2.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2024 15.21.2.1. By Drug Type 15.21.2.2. By Distribution Channel 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2024 15.22.2.1. By Drug Type 15.22.2.2. By Distribution Channel 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2024 15.23.2.1. By Drug Type 15.23.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Amgen Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Eli Lilly and Company 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Novartis International AG 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Gilead Sciences, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Teva Pharmaceutical Industries Ltd. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Merck & Co., Inc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Pfizer Inc. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. GlaxoSmithKline plc 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Roche Holding AG 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Johnson & Johnson 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Postmenopausal Osteoporosis Treatment Market
